ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Sep 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the role of blood platelets in autoimmune diseases, particularly systemic lupus erythematosus (SLE) and other related conditions like systemic scleroderma, ANCA vasculitis, inflammatory myositis, Gougerot-Sjögren syndrome, and rheumatoid arthritis. Researchers have found that in patients with these diseases, platelets can become overly activated and interfere with immune cells, which can worsen symptoms. The study aims to explore how platelets interact with immune cells in these diseases and whether targeting platelets could lead to new treatment options.

To participate in the trial, individuals must be between 18 and 70 years old and have a confirmed diagnosis of one of the conditions mentioned. They should also be able to understand the study's aims and risks and provide informed consent. Participants can expect to contribute to important research that may improve our understanding of autoimmune diseases and potentially lead to better treatments in the future. It's important to note that certain individuals, such as those under legal protection or in emergency situations, may not be eligible to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients between 18 and 70 years of age
• • Patient affiliated to a health insurance scheme (beneficiary or beneficiary's beneficiary)
• • Patient able to understand the aims and risks of research
• • Patient having signed and dated an informed consent form
• * Patient for whom the diagnosis of at least one of the following pathologies has been confirmed:
• • Systemic lupus erythematosus meeting ACR/EULAR 20195 classification criteria.
• • Systemic scleroderma meeting ACR/EULAR 20136 classification criteria.
• • ANCA vasculitis according to EULAR/ACR 2022.7-9 classification criteria.
• • Inflammatory myositis according to EULAR/ACR 201710 classification criteria.
• • Gougerot-Sjögren syndrome according to EULAR/ACR 2016 classification criteria11.
• • Rheumatoid arthritis according to ACR/EULAR 201012 classification criteria.
• Exclusion Criteria:
• • Patient in exclusion period (determined by a previous or current study)
• • Inability to give patient informed consent (patient in emergency or immediate life-threatening situation)
• • Patient under court protection
• • Patient under guardianship or curatorship